NASDAQ •
Healthcare •
Biotechnology •
Quote as of 09/09/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization5,751.28 mln
Float61.57 mln
Earnings Date10/22/2026
Piotroski F-Score
1
/ 9
Very weak
Beneish M-Score
-1.78
Likely manipulated
1-Year Forecast
99.29
Exceptional upside
Relative Strength
17
/ 100
Significantly lagging
Debt / Equity
-4.21
Negative equity
Pre-Tax Margin
-7%
Marginally loss-making
Business Description
PTC Therapeutics is a US-based drug development company focused on creating treatments for rare and serious conditions that affect both children and adults around the world. The company sells several approved medicines targeting diseases such as Duchenne muscular dystrophy, spinal muscular atrophy, and certain nervous system disorders, while also advancing a pipeline of new treatments for conditions like Huntington's disease and Friedreich's ataxia. PTC works alongside a number of notable partners, including Roche and Novartis, to develop and bring these therapies to patients. Founded in 1998 and headquartered in Warren, New Jersey, the company distributes its products through third-party partners across multiple markets.
